Clínic-IDIBAPS, a key role in developing the Hipra vaccine

by Fundació Clínic per a la Recerca Biomèdica

The HIPRA vaccine against COVID-19 is the first vaccine authorised for human health that has been designed and developed in Spain, and various services and units from both the Hospital Clínic Barcelo...

Read more

Un ensayo clínico de INCLIVA incorpora datos sobre el modo de vida de las pacientes de cáncer de mama para evaluar su salud ósea y mejorar su tratamiento

by INCLIVA

El Instituto de Investigación Sanitaria INCLIVA ha puesto en marcha un ensayo clínico sobre salud ósea de pacientes de cáncer de mama, en el marco del proyecto europeo REBECCA.

Read more

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

by Ysios Capital

Mineralys Therapeutics today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN...

Read more

Sant Pau empieza a administrar un nuevo medicamento CAR-T, de producción propia, contra linfomas B

by Hospital de la Santa Creu i Sant Pau

El Instituto de Investigación del Hospital de la Santa Creu i Sant Pau – IIB Sant Pau ha desarrollado un nuevo medicamento de inmunoterapia CAR-T que acaba de empezar a administrar, en el marco de ...

Read more

Los primeros resultados del estudio POSITIVE abren la posibilidad de un embarazo seguro a pacientes con cáncer de mama

by VHIO

La evidencia de este estudio pionero refuerza la idoneidad de apostar por la preservación de la fertilidad antes de iniciar el tratamiento oncológico y abre la posibilidad de un embarazo seguro para...

Read more

Results from SUNLIGHT study point to practice-changing care for patients with refractory metastastic colorectal cancer

by VHIO

A phase III clinical trial comparing the efficacy the combination of Trifluridine/tipiracil plus the antibody bevacizumab versus Trifluridine/tipiracil in patients with refractory metastatic colonrect...

Read more

Palobiofarma announces a collaboration with the Foundation for Prader Willi Research (FPWR) for the development of PBF-999 as a novel treatment for the Prader Willi Research syndrome

by Palobiofarma

FPWR’s philanthropic investment will be used to partially fund Palobiofarma’s ongoing Phase 2 clinical trial to develop PBF-999 for the treatment of Prader Willi syndrome (PWS).

Read more

Vall d’Hebron participa en una guía de recomendaciones para los ensayos clínicos con combinaciones de fármacos para el cáncer infantil

by Vall d’Hebron

Han participado en un documento de consenso mundial sobre recomendaciones para llevar a cabo ensayos clínicos de fase temprana con combinaciones de fármacos para el tratamiento del cáncer pediátri...

Read more

Almirall: Hasta el 73% de los pacientes con dermatitis atópica tratados con lebrikizumab logran un aclaramiento de la piel de la cara o las manos

by Asebio

Almirall ha anunciado recientemente los resultados de un análisis secundario del programa en fase III (estudios ADvocate y ADhere) que ha demostrado que los pacientes tratados con lebrikizumab mejora...

Read more

ORYZON reports financial results and corporate update for quarter ended March 31, 2023

by Oryzon Genomics

Oryzon Genomics, S.A. a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first ...

Read more

Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome

by Palobiofarma

Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study to investigate the potential of...

Read more

ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting

by Oryzon Genomics

Oryzon today announced the presentation of the trial in progress (TIP) FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myelo...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream